APP to launch Femara copy amid flattering data

Days after a study indicated that hormone-blocking pills called aromatase inhibitors can reduce the risk of breast cancer, generic drugmaker APP Pharmaceuticals said it will start marketing a version of the drug. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.